Week 1

  We started off our first week by performing a literature review on the key mechanisms of our section of the project, including the CRISPR-Cas9 wild type and Cas9 nickase mechanisms, as well as the FLP protein mechanism. Our literature search led us to design three plasmids to test the three main components of our subgroup project: ssDNA efficiency, FRT sequence insertion via Cas9n, and FLP recombinase efficiency. We decided that due to ease of access and high recombination frequency, wild-type CRISPR-Cas9 would be used in our initial ssDNA efficiency test, however due to its increased specificity largely aligning with our project's vision of safety, we decided to use Cas9n for the remainder of our project. As the week progressed, we continued to work out the foreseeable problems in our project and began to compile a list of faculty advisors whom we could contact for advice in shaping our project design. Throughout this planning process, we engaged in continuous discussion with the UCOE bros subgroup, to allow for our project design to be compatible and for our work to be done in parallel. Additionally, we attended the Laboratory Safety Training course held by the University of Calgary to prepare for our work in the laboratory.

Week 2

  This week we began meeting with faculty members and graduate students near our facility to discuss potential difficulties in our project. We met with grad student Taylor Goldsmith to discuss our current project design and decided to make some changes, most notably by replacing our CRISPR-Cas9n plasmid with ribonucleoproteins, which is known to increase recombination efficiency. By running a cost analysis, we were able to determine that RNPs are more beneficial to our project. Additionally, we were able to lay out an updated timeline of our project, including our main focus of verification and various side projects such as FLPo vs. FLPe characterization, circular vs. linear plasmid use for Cas9 insertion efficiency, and the use of a RNP-aptamer-ssDNA complex in facilitating Cas9 activity. In our spare time, our team was able to begin our human practices work by beginning our preliminary research in building a curriculum change proposal to the International Baccalaureate Organization.

Week 3

  This week, we focused on meeting with more faculty members to consult with in order to finalize our project design. We spoke to professors Wendy Anne Hutchins and Jonathon Lytton, who helped us troubleshoot our project. We also attended a "Methods Day" workshop hosted by the Department of Biochemistry and Molecular Biology, through which we were connected to some contacts who work with CRISPR as well as HEK cells. Meetings were set up with Iman Al Khatib, Justin Simms, and Tian Zhao, all graduate students at the University of Calgary working on similar projects. As the week progressed, we began putting together our plasmids on Benchling and communicating with the CME subgroup to ensure that our parts are compatible.

Week 4

  The focus of this week was a project presentation we held for our faculty mentors and graduate students whom we would like to engage with for the duration of the project. We were also able to have a meeting with the IB coordinator and IB Biology teacher from Father Lacombe High School, to further our process of building an option module focusing on synthetic biology, bioethics and its applications for the upcoming 2022 IB Biology curriculum change.

Week 5

  This week saw the management of ordering parts involving their finalization and ordering through IDT, Genscript and Addgene for various parts. In addition, laboratory work started via practice in transformations, overnights, minipreps and digest confirmations using registry parts that had potential for usefulness. PAH has importance in its mutation causing PKU, the AID gene has an enhanced GFP tag that could be used for reporting with Cas9, and we will be using a CMV promoter for transient expression of our parts. The Genscript and Promega funding applications were written and submitted.

Week 6

  *THIS ENTRY NEEDS EDITING* A continuation of laboratory practice was done using registry parts in waiting for parts to come in, transforming superfolding-GFP for reporting, dCas-omega as a potential way to verify insertion of FRT sites by CRISPR once we have transitioned to HEK cell work, the ECH and alpha-galactosidase genes for their implications in genetic disorders that may foreseeably be targets for our project. Considered using cDNA for the implementation of large genes to create functional proteins without splicing. In the lab, minipreps started to have low yields and through troubleshooting our process we determined that it was likely the isopropanol concentration that started to be used. Therefore, three parallel minipreps were done using 70%, 85%, and 100% isopropanol and it was found that there was a sharp increase in the concentration of isolated DNA when using increasingly higher concentrations of isopropanol, as a final concentration of 35% isopropanol is required in the solution.
  This week, we continued work in transforming (INCOMPLETE?)

Week 7

  This week saw the beginning of our HEK cell training and further optimization of experimental practices. The team learned to check the confluency, passage, set cells with a hemocytometer and to transfect HEK cells using a calcium/phosphate approach. After securing access to the Core facility (Snyder Bioinstrumentations Labs) at foothills campus, we were given an orientation of the area. Work on bacteria was furthered by practicing the use of electroporation and comparing relative efficiencies with chemical transformations. Various methods of gel extraction were performed, the most successful was catching DNA run on a gel on filter paper after its identity was confirmed, but it was determined it would be most efficient to buy a gel extraction kit that has a relatively low cost. Apart from the lab the Geekstarter application for funding was worked on exhaustively and submitted.

Week 8

  Parts started being received this week, allowing for set-up for the larger project to begin. pCAG-FLPo (came in Stbl3) and pCAG-FLPe (came in DH5-α) were digest confirmed. Our FLPo (Registry) part ordered from Genscript that will be used for submitting to the registry after ligation into a pSB1C3 backbone was digested and ligated for the first time. Electroporator testing was done by using varying concentrations of DNA. FRT-pUC57 sequence that is unfortunately incompatible with the other sub-group was transformed into DH5-α. Ligation transformations took two days to grow. Cas9 was linearized and Antarctic phosphatase treated to prepare for ligating sgRNAs into the plasmid once they are received.

Week 9

  Work in the lab consisted of troubleshooting digestion and ligations for FLPo (for the registry). We received our FRT halves from IDT as they could not synthesize our sequence of both FRT sites together due to hairpinning. We successfully inserted the FLPo sequence into pSB1C3, however after testing directionality, it was in backwards.

Week 10

  This week the sgRNA single-stranded oligos came in allowing for them to be annealed, ligated together and PNK treated. Our FRT 2nd half was not as successful as the first half in ligating into a pSB1C3 backbone, thus it was redone. Chemically competent DH5-α cells were made.

Week 11

  This week was repeating and troubleshooting the digestion and ligations of sgRNAs and Cas9, as well as ligating mCherry into pCAG-FLPo to add the CMV promoter to the front of mCherry. Sequencing results confirmed that the sgRNA ligations into the backbone were not successful.

Week 12

  Similar to last week, the focus this week was troubleshooting the sgRNA digestions as well as the mCherry digestion. Minor tweaks to concentrations were made and assays were re-attempted with different methods of purification, however we had no success. sgRNA insertion is still not working.

Week 13

  The same issues remain as in the last two weeks. FlpO-mCherry ligation was attempted and failed. The Cas9-sgRNA ligation was also re-attempted, and failed again. The issue is not BBsI as that was shown to work, however there may be another material problem resulting in our failed ligations.

Week 14

  The main objectives for this week were to ligate mCherry into the pCAG plasmid, ligate the sgRNAs into the Cas9 plasmid, and to ligate and transform the FRT 2nd half fragment ordered through IDT into pSB1C3. BBsI (the enzyme used for digestion of the Cas9 backbone for sgRNA insertion) was tested and shown to work, so that has not been our issue resulting in failed sgRNA transformation. No results were obtained with respect to FlpO and mCherry troubleshooting.

Week 15

  The purpose of this week was to begin planning our transfection system, and to continue attempting to ligate our sgRNA candidates into the pU6-Cas9 plasmid. Additionally, we attempted to clone mCherry into the pCAG-FlpO vector so that it would be attached to a promoter. No success was found with respect to sgRNAs or FlpO-mCherry. A homemade nucleofection buffer was made using sodium succinate based on literature review, which will be tested next week for effective nucleofection.

Week 16

  *EDIT THIS ONE, IT DOESN'T MAKE SENSE AND I DON'T KNOW HOW TO FIX IT* The problem of sgRNAs not ligating into the Cas9 backbone was solved, as in sequencing results, it was common to find what seemed to be undigested plasmid, despite the enzymes being new and tested otherwise knowing they are working. Thus antarctic phosphatase that was used on the Cas9 plasmid was investigated as the sgRNAs were PNK treated and the backbone if not AP treated will not ligate together and will only allow for the cut-out section to re-ligate making it look like there is only undigested plasmid. Therefore, new AP was ordered and the old AP was tested. The testing of old AP was a comparison between a digestion and ligation of our FLPo (registry) with itself and a digestion, Antarctic phosphatase treatment and ligation of FLPo (registry) with itself. It was shown that the growth of both after transformation was the same verifying that the old AP was non-functional, as if the AP worked the AP treated trial would have had ~5% of the non-treated samples growth. After this the sgRNAs were ligated into the Cas9 backbone with new AP and cPCR was used to verify insertion. Colony PCR was done using one of the complementary single stranded oligos and the single primer sgRNA IV together showing that single stranded oligos can be used as primers. From this, masterplates were made and from cPCR results the seemingly correct ones were overnighted and sent for sequencing. HEK cells were nucleofected with GFP using home-made buffer and compared the usefulness of two types of cuvettes, finding which type of cuvettes to use in the future. FLPo (registry) was attempted to be reversed, but the directionality was not fixed. pCAG-mcherry work has continued to be troublesome due to pCAG-FLPo not running properly, but pCAG-FLPe was attempted for ligation as an alternative. It is also apparent that gel purification can still be done despite the nanodrop reading that there is no DNA due to running it on a gel and having a very clear and correct band.

Week 17

  Further tests on the relative compatibility of the two brands of nucleofection cuvettes were assessed due to potential human error in the first run. The results of these tests confirmed that one type of cuvette was about 40% more efficiency for nucleofection. sgRNA sequencing results came in and showed successful sgRNA ligation in five of eight samples, thus those that did not work initially were re-ligated, transformed, cPCRed, overnighted, miniprepped and sent for sequencing. This second round of sgRNA sequencing revealed that we have seven out of eight sgRNAs ligated in. The missing one is CCR5 1-7R. The seven successful sgRNAs will be tested next week, while we attempt to clone CCR5 1-7R.

Week 18

  This week, targeting efficiency of our various sgRNAs was tested and the relative effectiveness of Cas9-WT (wild type) and Cas9n (nickase) were compared. This was accomplished by transfecting our sgRNA-Cas9 plasmids into HEK293 cells using Lonza nucleofection with the homemade buffer, which was tested in previous weeks. For the wild type vs. nickase trial, HEK293 was transfected with a combination of Cas9n or Cas9-WT, as well as the corresponding sgRNA and ssDNA template for insertion. In both trials, a no transfection control and GFP-transfection control were used. In total, 7 sgRNA candidates were transfected, as well as Cas9n and Cas9-WT. However, after purifying gDNA (genomic DNA) from the transfected cells two days later and running them in a PCR reaction, no amplified fragments appeared.

Week 19

  This week was used to troubleshoot the lack of gDNA PCR bands from last week. We predicted that the fault lay with our gDNA extraction technique, so a variety of gDNA extraction techniques were performed to test for the most effective. This included protocols from classes, workshops, proteinase K treatment, and a cell lysis buffer. However, after using the purified DNA for PCR, none of the extraction methods showed promise.

Week 20

  A variety of methods of DNA isolation were attempted on the HEK 293T cells, in which it was found that the basic "strawberry extraction" technique worked to extract the DNA. This extracted DNA was ethanol precipitated and prepared to run a gPCR reaction. Outside of the lab, work on the aGEM project outline and video pitch was started and completed for the deadline on Friday. Past this, work on the formal presentation for aGEM began. Final designs for our hybrid FlpO-beta resolvase plasmid, as well as the corresponding ssDNA, were made and the parts ordered.

Week 21

  **GUYS THIS NEEDS EDITING TOO, PARTICULARLY THE FIRST SUPER LONG SENTENCE** This week gPCR was run with poor results, not providing bands for extraction, purification and sequencing, thus troubleshooting was done, identifying the melting temperature of the primers to be a potential source of error within the gPCR method, due to a variety of sources giving different melting temperatures for the same primer (with a 10° Celsius range). HEK cells were thawed to prepare for future experiments to be done with the Flp/beta-resolvase hybrid part that was expected to come in soon. Preparation for the aGEM conference was a focus of the week on building and solidifying the presentation. Two mentors/advisors, Dr. Dalton and Rachelle Varga provided feedback before aGEM, helping focus the presentation on aspects that were most important.

Week 22

  **PLEASE EDIT SECOND SENTENCE** Using the control transfected HEK293T cells a genomic DNA extraction "miniprep" kit was tested, as a potential source of error in PCR (not having genomic DNA enough or sheared too heavily for primers to work effectively). Initial PCR reactions done with these samples were unsuccessful, returned to the strawberry extraction and similarly also failed when run on a gel (no bands, only smears). Along with these, tests on various melting temperatures (53°C, 57°C) were done to attempt finding an optimal melting temperature.

Week 1

  We began an extensive literature search on the topic of insulators and other epigenetic regulatory elements. We determined that ubiquitous chromatin remodeling elements (UCOEs) would be effective at opening chromatin and will be very useful in producing continuous high-level transcription of any transgenes that are inserted into the human cell genome via our CRISPR/FLP system. While UCOEs will allow for our gene to enter an active transcriptional state, insulators will function to maintain this state. If flanking the transgene, insulators protect the gene from the spread of neighboring heterochromatic regions and from crosstalk of enhancers. In addition, we began a discussion about the testing platform that we will utilize. Working in parallel with the CRISPR subgroup prevents us from using their integration scheme, so we are investigating other options for preliminary experiments. We also completed all necessary Lab Safety training which will allow us to work in the lab this summer.

Week 2

  We continued with literature research specifically focused on ubiquitous chromatin remodeling elements (UCOEs) as well as insulators. The A2UCOE, CBX3-UCOE, and cSH4 insulator were selected for experimentation and their sequences were obtained. We began planning constructs which will eventually constitute the various cassettes during recombinase mediated cassette exchange (RMCE) procedures. We continued the investigation of other options for preliminary experiments that will free us from dependence on the CRISPR subgroup's FRT integration scheme. One promising approach would be to generate minicircles from triple-FRT containing FLP plasmids within prokaryotic cells, isolate and purify the minicircles, and co-transfect them with plasmids expressing FlpO (pCAG-FLPo) into a HEK cell line that already contain one FRT site, such as the Flp-In T-REx HEK293 cells available commercially. This would allow for the insertion of a second heterospecific FRT site, which makes RMCE possible. Therefore, we could conduct our experiments on UCOEs and insulators while the CRISPR subgroup fine-tunes the CRISPR-mediated FRT integration scheme. We began a discussion about the process of obtaining the Flp-In T-REx HEK293 cells from internal contacts within the University of Calgary. Another promising possibility explored is to obtain a cell line that already contains heterospecific FRT sites. In this case, we could begin immediately with RMCE in order to investigate UCOE and insulator function. We contacted the principle investigator from that research group in regards to obtaining cells from the generated cell line and are awaiting a response.

Week 3

  This week, we finalized our BioBrick plans including the restriction sites to be used. Further research on the characteristics of these restriction sites was also conducted. After meeting with Dr. Ray Wang, we secured access to the Flp-In T-REx HEK293 cell line as well as the commercial vectors pcDNA5 and pOG44 designed for use in the system. Dr. Ray Wang also offered to provide troubleshooting assistance to the team when using this system. We practiced laboratory techniques by transforming chemically competent DH5-α cells with a CMV promoter (BBa_I712004) and a BGH terminator (BBa_K1150012), and chloramphenicol resistance (BBa_K143064). The University of Calgary also hosted a methods day, where we were able to attend presentations and speak to other researchers regarding certain laboratory techniques and protocols. In particular, we learned more about bisulfite sequencing, transfection techniques, and qPCR primer design. Our team also attended a welcome event for summer students, where we went bowling as a team-building activity. Finally, we helped to prepare slides and script for a presentation that will be given to mentors, industry professionals, and other interested general public attendees on May 23rd.

Week 4

  This week, we continued working on our transformed DH5-alpha cells for practice, including creating overnights, mini-prepping, running a digest, and a digest confirmation. In addition, we created approximately 70 aliquots of chemically competent DH5-alpha cells for later use. We transformed the parts required for Interlab into our chemically competent DH5-α cells and left them to grow over the weekend. Growth was slow, therefore we will re-transform the Interlab parts next week with an improved transformation protocol that will hopefully result in a normal growth rate.
We finalized the restriction sites that will be used in collaboration with the CRISPR subgroup to ensure that all parts are compatible, and that we are ordering sequences in the most efficient way possible. In addition to participating in the Innovate Calgary workshop, we also contributed to a team presentation in which we revealed our project idea and experimental plan to faculty experts, mentors, and members of the public. This event was very useful as we were able to identify some strengths and weaknesses of the project and plan as well as other general feedback from the audience.

Week 5

  We received very generous samples of T-Rex Flp-In HEK293 cells and pcDNA5 and pOG44 vectors from Dr. Ray Wang, a researcher in Dr. Wayne Chen's lab here at the University of Calgary. The cells were stored at -80C while the pcDNA5 and pOG44 vectors were transformed into chemically competent DH5-α. We miniprepped several samples of pcDNA5 and pOG44 from the cells and have stored them in the freezer for use later in the summer. We also made glycerol stocks of both vectors for long-term storage.
  We re-transformed all of the Interlab test parts in chemically competent DH5-α. During the transformation we used a lower volume of recovery media and lengthened the recovery incubation. All of the transformations grew much quicker than last week, therefore we will use the new, faster-growing parts for the remainder of the Interlab study.
  Addgene was offering free synthesis of 2kb gene fragments. We took full advantage of this offer and ordered a few of our constructs: mCherry-BGH, which will be ligated to CMV (BBa_K747096) from the distribution kit, and both CHS4 insulator parts. Before CMV is ligated to mCherry-BGH, we will use overhang PCR to add a SalI restriction site upstream of the promoter. This will improve the part and allow it to function with our construct system.

Week 6

  We began the week by testing electroporation protocols using our electrocompetent cells and the competent cell test kit. The first protocol that we tried was very successful, and we saw very high transformation efficiencies. This allowed us to conclude that electroporation will be the method of choice for transforming more important parts into DH5-α cells. We also created a plasmid stock of the vectors pcDNA5 and pOG44 for later use in HEK293 Flp-in T-REx cells. We tried to miniprep and digest confirm the remaining Interlab test parts, but continued to get unexpected results. Therefore, we re-transformed test parts 1, 5, and 6 (BBa_J364000, BBa_J364008, BBa_J364009). We designed PCR primers with overhangs to add restriction sites to CMV from the registry that will later be cloned with an mCherry-BGH construct to form our insert. We conducted more in depth research into methods and protocols for qPCR and bisulfite sequencing. Since IDT was unable to synthesize our UCOEs, we contacted Genscript and they provided us with a quote. Finally, we investigated using Gibson assembly as an alternative method for assembling our constructs.

Week 7

  We determined that the cloning method we will proceed with will be the traditional restriction enzyme cloning, while other members of the team may later pursue Gibson assembly if our method is not working. Having decided that we would PCR amplify the subpart of A2UCOE that constitutes CBX3-UCOE as a method for staying on budget, we ordered only A2UCOE from Genscript. We finished the CMV overhang-primer design on Monday and ordered them from the University of Calgary DNA services. We miniprepped pSB1C3-CMV that the CRISPR subgroup had previously transformed and digest confirmed, and then ran PCR to generate CMV with restriction sites that we will need. The product was run on a gel and appears to be the correct size, so we proceeded with a digest. Our mCherry-BGH and one of the insulators that had been ordered as free samples from Genscript arrived on Friday, and will be used early next week. For the Interlab, we miniprepped and digest confirmed the parts once more, and decided to proceed. We attended an orientation at the Snyder Core Facility, which is where the fluorescent plate reader that we will need to use for the Interlab study (as well as the qPCR machine) is located. Following more in depth training in the Snyder Core Facility, we will be able to complete the Interlab study. We helped train the CRISPR subgroup in using electroporation. Finally, we participated in HEK cell training, including passaging and transfecting cell cultures.

Week 8

  This week, our ordered parts arrived and we began to clone them into pSB1C3. We digested our mCherry DNA block, the CMV PCR products with XbaI and PstI, and a previously miniprepped backbone sample which we then ligated. Simultaneously, we digested both the cHS4 insulator DNA blocks, as well as more backbone with XbaI and SpeI then ligated. After some ligation troubleshooting, we proceeded to transform chemically competent DH5-α cells with the ligation products as well as electroporate some samples. However, as of Friday these transformations were unsuccessful. Aside from the wet lab work, we collaborated with the dry lab team to discuss wiki content for our subgroup. In addition, we researched some protocols that will be used later this summer. Finally, we read the Thermofisher manuals for the T-REx HEK 293 cells that we will begin to use in the future.

Week 9

  We began the week by screening colonies from the ligations of our parts into pSB1C3 using digest confirmations. The first colonies screened did not contain the correct inserts, but on the second attempt, we found some colonies that appeared to possibly contain our improved pSB1C3-CMV and pSB1C3-mCherry-BGH. These samples were sent for sequencing and we are awaiting the results. As we had issues with trying to ligate the cHS4 insulators into pSB1C3 using XbaI and SpeI sticky ends, we repeated the ligation using a 7:1 insert to vector ratio. The ligation products were transformed into chemically competent DH5-α, and we screened some of the new colonies. Unfortunately, all the results were negative. Outside of the lab, we completed the iGEM Safety Form 1, and began writing content and creating figures for our wiki pages.

Week 10

  Early in the week, we completed a large portion of the Interlab study by generating the required standard curves. We received the sequencing results for the suspected improved pSB1C3-CMV and pSB1C3-mCherry-BGH, but the sequences were not as expected. It appeared that what we suspected to be the backbone with the correct insert was actually residual undigested backbone, even though we had gel-extracted it before ligation. These parts were digested and ligated once more.
  After using digest confirmations to screen approximately 60 colonies in the first half of the week, we discovered a colony PCR (cPCR) protocol that would optimize and streamline our colony screening process. We tested this protocol using the positive control from the Interlab study (BBa_I20270) in order to determine which buffer and Taq polymerase combination works best. Having isolated the best combinations, we are confident implementing this solution moving forward.

Week 11

  We began the week by repeating some transformations as well as digests and ligations of the cHS4 insulators and the improved CMV product into pSB1C3. In addition to trying to ligate the insulators into pSB1C3 using XbaI and SpeI sites (as the Genscript part is missing the NotI site from the prefix and suffix), we also attempted to use the EcoRI and PstI sites. Using colony PCR (cPCR), we were able to screen approximately 130 colonies with ease. We found one colony with pSB1C3-mCherry-BGH, and ran an addition digest confirmation as well as sent a sample for sequencing. We were also able to find four colonies for the E/P-digested pSB1C3-cHS4(1) and one for E/P-digested pSB1C3-cHS4(2). The ligation of improved CMV into pSB1C3 produced no colonies, but we moved ahead with ligating the improved CMV into pSB1C3-mCherry-BGH, and transforming the product. These colonies will be screened next week. In order to perform experiments to test the function of our CMV as an improved part, we also began steps to clone the original CMV promoter from the registry into pSB1C3-mCherry-BGH. Finally, as the E/P digest-ligations worked so much more efficiently than those with X/S, we began investigating alternative methods for correcting the NotI sites on the cHS4 insulators within the backbone.

Week 12

  As the CRISPR subgroup was mostly absent this week, we assumed their task of cloning together the two halves of the multiple cloning site (MCS). IDT was unable to synthesize the MCS as one part due to hairpins. Early in the week, we worked on digesting and recovering each half for ligation. The MCS first half was successfully digest confirmed, sequenced, and set aside for ligation. However, after several failed digests and sequencing, we concluded that the CRISPR subgroup's 'MCS second half' glycerol stocks actually contained empty backbone. Before we can move forward with joining the two halves, we will need to ligate the IDT Biobrick MCS second half into pSB1C3.
  Our pSB1C3-mCherry-BGH sequencing results came back early in the week, and the part is exactly as expected. We are confident moving forward with cloning. We continued to screen pSB1C3-mCherry-BGH + improved CMV ligation colonies using cPCR, but so far we have not found a colony with the correct insert. As all of our improved CMV ligations have been unsuccessful, we began research into possible causes. We found that impurity of PCR products may be a factor, and therefore tried to gel purify our product. However, our gel purification kit failed once again. Next week, we plan to make new improved CMV and excise the correct band from LMP gel before digesting and ligating.
  Sequencing results for both cHS4 insulators ligated using E/P showed that the correct part was inserted, but as suspected, the NotI site was mutated. This was further verified by a digest confirmation. In order to submit these parts, we will have to follow a two-step cloning process beginning with XbaI and PstI digestions. Colonies were screened using cPCR. Over the course of the week, we found only three colonies for the pSB1C3-cHS4(2) X/P ligation that appeared to have the correct insert. These will be sequenced next week.
  As we intend to submit our new CMV as an improvement on CMV (BBa_K747096) from the iGEM registry, we also worked on cloning this part into pSB1C3-mCherry-BGH. After experiments meant to quell some doubt regarding the identity of glycerol stocks made by the CRISPR subgroup, we were able to digest pSB1C3-CMV with XbaI and SpeI and recover the insert via LMP gel extraction. Ligation into pSB1C3-mCherry-BGH will occur next week.

Week 13

  We began the week with an attempt to ligate the second half of the MCS into the pSB1C3 backbone with two different methods. One of the methods produced no growth after ligation, while the other did produce colonies. These colonies were screened using cPCR, and the initial results were promising. Some of the colonies containing inserts of the correct size were miniprepped and sent for sequencing. However, a failed digest confirmation has caused us to doubt the part's identity. We also stockpiled many more samples of parts and backbones that we may need in the future
  Overnights were made and miniprepped for insulator samples. These were digest-confirmed, and then we moved onto the next round of ligations with them in order to incorporate the NotI sites. We also digested each of the insulators with their corresponding MCS restriction enzymes and stored them in the freezer in preparation for future cloning.
  We also continued trying to digest and ligate our CMV PCR product into the pSB1C3 backbone but had no definite success this week. Efforts will continue next week.

Week 14

  As we suspected last week, the supposed pSB1C3-MCS was determined to be an incorrect part via sequencing and further digest confirmations. As it may not be entirely necessary to clone the second half into pSB1C3 individually, we moved on to cloning the IDT Biobrick into pSB1C3-MCS first half directly using NsiI and SpeI sites. However, we were not yet successful as of Friday.
  We also continued to clone the CMV promoters into pSB1C3-mCherry-BGH, but did not advance to the stage of screening colonies. Midway through the week, we discovered that the glycerol stocks of pSB1C3-CMV that the CRISPR subgroup had created (the ones we have recently been using) may have been from a different registry part than the one we intended to use (BBa_I712004 vs. BBa_K747096). Therefore we retransformed the pSB1C3-CMV that we had originally planned to use (BBa_K747096), made new glycerol stocks, and miniprepped some samples. We then performed extension PCR on the new samples, the product of which was subsequently digested and prepared for ligation.
  Finally, we continued with our attempts at cloning the cHS4 insulators into pSB1C3 so that they have both NotI sites. We believe that we were able to clone pSB1C3-cHS4(2), but we will digest confirm and sequence this sample next week.

Week 15

  We began the week by repeating the ligation of MCS second half into pSB1C3-MCS first half. After cPCR screening and preliminary digest confirmations, we believe that we have successfully cloned the whole MCS into pSB1C3. More digest confirmations will be performed next week.
  In addition, we believe that we have successfully ligated the MCS second half fragment into pSB1C3. We will confirm this next week.
  We were also able to confirm via digests and sequencing that we have successfully inserted cHS4(2) (which has the same sequence as cHS4(1) aside from two flanking restriction sites) into pSB1C3 for submission to the registry.
  Finally, we continued attempts to clone the improved CMV into pSB1C3 and pSB1C3-mCherry-BGH, as well as the original CMV (BBa_K747096) into pSB1C3-mCherry-BGH. Though we have not yet had success with the improved CMV, cPCR results lead us to believe that we have successfully ligated the old CMV into pSB1C3-mCherry-BGH. This is essential for allowing us to test our improved part's function. The colonies suspected to contain this part will be characterized further next week.

Week 16

  We were able to confirm that the suspected pSB1C3-MCS was indeed the correct part containing all of the necessary cloning sites using digest confirmations. This part can now be used in future cloning and will also be submitted to the registry. Before any of the constructs can begin to be made, we first needed to clone our improved CMV into pSB1C3-mCherry-BGH. Therefore, the majority of our efforts this week focused on cloning these parts together, as well as cloning our improved CMV directly into pSB1C3. Though the former was not yet successful, we believe that we have successfully cloned improved CMV into pSB1C3. Samples were sent for sequencing and we are awaiting results. In parallel, we also set up digest confirmations of the miniprepped the improved pSB1C3-CMV samples using pSB1C3-CMV (BBa_K747096) as a control. The results were exactly as expected.
  We sent the supposed pSB1C3-MCS second half for sequencing early in the week. However, the results we recieved indicate another unsuccessful ligation.
  In preparation for characterization of our improved part, we also digested pSB1C3-CMV-mCherry-BGH and pcDNA5 (our Flp-In vector that will be used in HEK 293 T-REx cells) so that we may ligate them together next week.

Week 17

  Early in the week, we received sequencing results for the improved pSB1C3-CMV and were able to determine that we had successfully ligated in the correct insert. We proceeded with ligating this promoter to our reporter, pSB1C3-mCherry-BGH. cPCR screening indicated that this ligation was also successful, so we sent samples for sequencing and began preparing to create our constructs by digesting this part for ligation into pSB1C3-MCS. However, the initial digestion of pSB1C3-improved CMV-mCherry-BGH failed.
  In order to characterize our improved parts, we also began working on cloning mCherry-BGH and CMV-mCherry-BGH into our eukaryotic T-REx HEK293 vector pcDNA5, though initial attempts were unsuccessful.
  We finally received our pUC57-A2UCOE part from Genscript after many months, as the GC-rich sequence gave them lots of difficulty during synthesis. This part was transformed and digest confirmed, and we set up a digestion over the weekend in order to ligate it into pSB1C3.

Week 18

  We continued the attempts at cloning the mCherry-BGH, CMV-mCherry-BGH, and improved CMV-mCherry-BGH parts into pcDNA5. However, after repeated attempts, we have still not yet been successful.
  Early in the week we received sequencing results that confirmed the identity of the pSB1C3-improved CMV-mCherry-BGH part. We had to do some troubleshooting with the restriction enzymes that we were using to digest it, but even after a successful digestion, we had a failed ligation. It is beginning to look impractical to make all of our constructs in the remaining time before the competition.
  We also ligated A2UCOE into pSB1C3 and after an initial cPCR screen, discovered one colony that contained the correct insert. This will be further verified next week.

Week 19

  As our fall semester of university began again this week, much of our time was spent cleaning up the lab. Aside from this, we continued with attempts at cloning the mCherry-BGH, CMV-mCherry-BGH, and improved CMV-mCherry-BGH parts into pcDNA5. We also prepared pSB1C3-A2UCOE for a digest confirmation.

Week 20

  We continued to work on cloning the mCherry-BGH, CMV-mCherry-BGH, and improved CMV-mCherry-BGH parts into pcDNA5 using various samples and vector:insert ratios, but still did not have any success.
  The pSB1C3-A2UCOE colony identified via cPCR two weeks past was digest confirmed, but the results were unclear. Therefore we repeated this ligation and transformed it.

Week 21

  We began the week by once again attempting the ligation of mCherry-BGH, CMV-mCherry-BGH, and improved CMV-mCherry-BGH into pcDNA5. After once again failing, we decided to change our approach and use a new vector. Due to accessibility, we chose to work with pEGFP-N1, but had issues early on with this. We then investigated the possibility of characterizing our improved part in a prokaryotic chassis rather than eukaryotic, which proved possible. In order to do so, we transformed DH5-alpha with pSB1C3-mCherry (BBa_J06602) from the distribution kit which contains an RBS for prokaryotic transcription.
  We continued efforts to clone our new A2UCOE part into pSB1C3, and near the end of the week received positive results in a cPCR screen. These results will be confirmed further next week.
  Over the weekend, we hosted aGEM, where we presented our project and participated in workshops along with 5 other iGEM teams from Alberta.

Week 22

  Early in the week, we digest-confirmed the newly transformed pSB1C3-mCherry (BBa_J06602) then moved forward with ligating both the old CMV (BBa_K747096) and our improved CMV to this part. Initial cPCR screens indicated that these ligations were successful and many of the colonies on these plates turned red. We will further confirm these preliminary results next week.
  A successful digest confirmation was run for the colony of pSB1C3-A2UCOE that was identified as having the correct insert via cPCR screening last week. We also sent this part for sequencing, and were able to determine that the sequence is exactly as expected.
  Finally, we began concrete planning for a collaboration with the Notre Dame iGEM team which was initially discussed last week at the aGEM meetup.

Week 23

  Throughout the week, we cPCR-screened multiple red colonies from each of the pSB1C3-CMV-mCherry-BGH ligations. We ran confirmation digests on colonies that appeared to have the correct insert, and were able to determine that our ligation and part improvement was successful.
  We also began efforts to clone our team's final part, 'Flp/beta resolvase hybrid' into pSB1C3 in order to assist the CRISPR subgroup.

Week 24

  The main focus of this week was our collaboration with the Notre Dame iGEM team. We hosted a graphic design workshop and oriented them to our lab early in the week, and then ran spectrophotometry experiments with them later in the week using our spectrophotometer as they did not have access to one.
  We finished cloning and confirming our new part, pSB1C3-Flp/beta-resolvase hybrid and submitted all of our new and improved parts to the registry.
  Later in the week, we began more serious work on our wiki and presentation, as well as some other applications for local research symposiums.

Week 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas vitae feugiat odio. Morbi luctus lacus in suscipit ultrices. Suspendisse quis ultricies sapien. Vestibulum vitae massa eu dolor cursus aliquam vitae eget neque. Mauris a turpis nec mauris luctus blandit. Nunc suscipit, nisl nec fringilla placerat, magna nisi imperdiet est, nec interdum quam nulla nec quam. Nunc ligula dolor, convallis quis placerat eget, dapibus ut diam. In quis iaculis magna, a tristique magna.

Week 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas vitae feugiat odio. Morbi luctus lacus in suscipit ultrices. Suspendisse quis ultricies sapien. Vestibulum vitae massa eu dolor cursus aliquam vitae eget neque. Mauris a turpis nec mauris luctus blandit. Nunc suscipit, nisl nec fringilla placerat, magna nisi imperdiet est, nec interdum quam nulla nec quam. Nunc ligula dolor, convallis quis placerat eget, dapibus ut diam. In quis iaculis magna, a tristique magna.